CRISPR Therapeutics GS presentation fails to excite investors, shares down 7%

|About: CRISPR Therapeutics (CRSP)|By:, SA News Editor

CRISPR Therapeutics (CRSP -6.9%) slumps on more than 40% higher volume following its corporate presentation at Goldman Sachs' Healthcare Conference. Investors are behaving like they were disappointed with what was said.

CRISPR/Cas9 competitors Intellia Therapeutics (NTLA +1.8%) and Editas Medicine (EDIT +1.8%) are holding their own.

Subscribe for full text news in your inbox